lncRNAs are novel biomarkers for differentiating between cisplatin-resistant and cisplatin-sensitive ovarian cancer

Cisplatin-resistant ovarian cancer occurs in patients with ovarian cancer treated with cisplatin-based chemotherapy, which results in tumor progression during treatment, or recurrence of the tumor within 6 months of the treatment. It is vital that a novel biomarker for diagnosis, or an efficient the...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Qing, Zhang, Juan, Zhou, Juan, Yang, Binglie, Liu, Pingping, Cao, Lei, Jing, Lei, Liu, Hua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2018
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5950027/
https://www.ncbi.nlm.nih.gov/pubmed/29805570
http://dx.doi.org/10.3892/ol.2018.8433

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5950027/
https://www.ncbi.nlm.nih.gov/pubmed/29805570
http://dx.doi.org/10.3892/ol.2018.8433

Ejemplares similares